Lupin has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly’s drug Baricitinib in India.
Lilly has received permission from Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for restricted emergency use of Baricitinib in combination with Remdesivir for the treatment of suspect or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients. With a rapid increase in active COVID-19 cases in India, the timely restricted emergency use of Baricitinib will be an important life-saving treatment for patients with moderate to severe symptoms of COVID-19.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1907.15 |
| Dr. Reddys Labs. | 1359.25 |
| Cipla | 1459.55 |
| Zydus Lifesciences | 1149.70 |
| Lupin | 2486.90 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: